rawfin.tv
Insight Molecular Diagnostics Projects $0.25M Q2 Revenue, Over $9M Cash Burn
EarningsstocksAI Generated

Insight Molecular Diagnostics Projects $0.25M Q2 Revenue, Over $9M Cash Burn

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Insight Molecular Diagnostics (IMDX) anticipates approximately $0.25 million in revenue for Q2 2026, alongside a projected cash burn exceeding $9 million for the same quarter. The company's Q1 2026 earnings call also provided updates on FDA progress for GraftAssureDx and launch timing.

IMDXrevenuecash burnbiotechearnings

Related Articles

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

stocks
Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

stocks
Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

stocks
Barclays Workforce Trimmed 5% as Bank Increases Focus on AI

Barclays Workforce Trimmed 5% as Bank Increases Focus on AI

stocks